← All trials
NCT06943950
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2025
- Primary completion
- Apr 28, 2027
- Completion date
- Jun 30, 2027
- First posted
- Apr 25, 2025
- Last posted
- Apr 30, 2025
- Enrollment
- 500
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yiling Pharmaceutical Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.